RISPERDAL® CONSTA® (risperidone) Long Acting Injection

BACK TO PREVIOUS
También en Español
Full US Prescribing Information
Sitemap
Global Resources
Tell a friend
Privacy Policy
Legal Notice
Printer Friendly
 Text Size:  S | M |  L
 
 
 
    

SiteMap


HOME

For Patients
About Schizophrenia
Who is Affected by Schizophrenia?
Symptoms of Schizophrenia
Causes of Schizophrenia

Diagnosis of Schizophrenia

Living with Schizophrenia
Treating Schizophrenia
Importance of a Healthy Lifestyle
Benefits of Regular Exercise
Benefits of Eating Healthy
About Relapse
Evolution of Treatment

About RISPERDAL CONSTA
HOW RISPERDAL CONSTA May Help You
RISPERDAL CONSTA and Oral Medications
How Does RISPERDAL CONSTA Work?
Getting Started on RISPERDAL CONSTA
Side Effects
Getting the Most Out of Treatment

Staying on Treatment
Importance of Staying on Treatment
Challenges of Staying on Treatment
Taking Your Medication as Prescribed? Try this "Quick Quiz".
Tips to Remember Your RISPERDAL CONSTA Injection
Appointments
Tools to Help You Stay on Treatment
Schizophrenia Newsletter

News Center

Resources
Patient Assistance Program
Mental Wellness.com
Links to Other Sites
Recommended Reading

Frequently Asked Questions
 
For Caregivers
 
For Healthcare Professionals
 
For Billing Support
 
Important Safety Information
 
Privacy Policy
Legal Notice
Full U.S. Prescribing Information
Contact RISPERDAL CONSTA
Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. Corporate Web Site
Legal Statement
 
Frequently Asked Questions
Frequently Asked Questions
For frequently asked questions about RISPERDAL CONSTA, click here.
Patient Brochure
Patient Brochure View and download
RISPERDAL CONSTA patient education brochure. Click here.

 


RISPERDAL® CONSTA® (risperidone) is used for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL® CONSTA®

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL® CONSTA® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL® CONSTA® and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL® CONSTA® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL® CONSTA® and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL® CONSTA®. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL® CONSTA® and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

Some people taking RISPERDAL® CONSTA® may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect can be reduced or it may go away over time.

RISPERDAL® CONSTA® may affect your alertness or driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® CONSTA® should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Inform your healthcare professional if you become pregnant or intend to become pregnant during therapy with RISPERDAL® CONSTA®. Caution should be exercised when RISPERDAL® CONSTA® is administered to a nursing woman.

RISPERDAL® CONSTA® may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

Some medications interact with RISPERDAL® CONSTA®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while on RISPERDAL® CONSTA®.

In a study of people taking RISPERDAL® CONSTA®, the most common side effects in the treatment of schizophrenia were headache, tremors, dizziness, restlessness, tiredness, constipation, indigestion, sleepiness, weight gain, pain in the limbs, and dry mouth.

If you have any questions about RISPERDAL® CONSTA® or your therapy, talk with your doctor.

For more information, read the Important Product Information by clicking here.

01CS1054




Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Home   Janssen.com   Site Map   Contact Us   

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003 – 2008. This site is published by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents. This site is intended for visitors from the United States.
This page was last updated on: Jan 18 2008 at 13:39:18 EST